Patents Assigned to Georgetown University
  • Patent number: 11357742
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 14, 2022
    Assignees: X4 Pharmaceuticals, Inc., Georgetown University, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Robert D. Arbeit, Paula Marie Ragan, Michael B. Atkins, James W. Mier, David McDermott
  • Publication number: 20220168277
    Abstract: A method for treating against, or at least inhibiting or suppressing, the proliferation of a cancer involves administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting metastasis of cancer cells, wherein the compound is represented by the formula (1): wherein each R1 is independent of the other and represents a halogen atom selected from the group consisting of bromo, chloro, fluoro and iodo.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 2, 2022
    Applicants: HOWARD UNIVERSITY, GEORGETOWN UNIVERSITY
    Inventors: Hemayet ULLAH, Sivanesan DAKSHANAMURTHY
  • Patent number: 11311526
    Abstract: Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: April 26, 2022
    Assignees: Georgetown University, The Board of Regents of the University of Oklahoma
    Inventors: Milton L. Brown, Yali Kong, Courtney Houchen, Sripathi M. Sureban, Parthasarathy Chandrakesan
  • Patent number: 11311606
    Abstract: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin ?-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: April 26, 2022
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Christopher Albanese, Aisha Naeem
  • Publication number: 20220104732
    Abstract: A device for introducing at least one antimicrobial in an exposed region of a user's skin caused while accessing interstitial fluid includes a substrate having thereon at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion for forming a micropore in the user's skin. A nanofiber mat loaded with at least one antimicrobial material is arranged on the substrate such that it contacts the user's skin and encircles an opening of the micropore formed by the microheating element. In a preferred embodiment, the at least one antimicrobial material is LL-37.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: Georgetown University
    Inventors: Makarand Paranjape, Shruti M. Paranjape
  • Patent number: 11295417
    Abstract: A system and method are described for enhancing readability of document images by operating on each document individually. Monochromatic light sources operating at different wavelengths of light can be used to obtain greyscale images. The greyscale images can then be used in any desired image enhancement algorithm. In one example algorithm, an automated method removes image background noise and improves sharpness of the scripts and characters using edge detection and local color contrast computation.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: April 5, 2022
    Assignee: Georgetown University
    Inventors: Ophir Frieder, Gideon Frieder, Jon Parker
  • Publication number: 20220096442
    Abstract: A method for treating against, or at least inhibiting or suppressing, the proliferation of an internal ribosome entry site-utilizing virus (IRES-utilizing virus) involves administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the IRES-utilizing virus in cells, wherein the compound is represented by the formula: wherein each R1 is independent of the other and represents a halogen atom selected from the group consisting of bromo, chloro, fluoro and iodo.
    Type: Application
    Filed: October 29, 2019
    Publication date: March 31, 2022
    Applicants: HOWARD UNIVERSITY, GEORGETOWN UNIVERSITY
    Inventors: Hemayet ULLAH, Sivanesan DAKSHANAMURTHY
  • Patent number: 11280797
    Abstract: The present invention relates to methods of determining if a subject has a decreased risk of suffering from future memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has a decreased risk of suffering from future memory impairment compared to a normal individual.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 22, 2022
    Assignees: Georgetown University, University of Rochester
    Inventors: Mark E. Mapstone, Howard J. Federoff, Massimo S. Fiandaca, Amrita K. Cheema
  • Patent number: 11278551
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 22, 2022
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Jill P. Smith, Louis Weiner, Sandra Jablonski, Sandeep Nadella, Shangzi Wang
  • Patent number: 11278522
    Abstract: Previous studies (Xiao et al., 2001) have identified two metabolites of methadone, EMDP (2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline) and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), which are considered to be inactive at opiate receptors, as relatively potent noncompetitive channel blockers of ?3?4 nAChRs. We have now evaluated these compounds in rats and mice in preclinical behavioral models predictive of potential anxiolytic and antidepressant efficacy. We found that EMDP, but not EDDP, displayed robust effects predictive of anxiolytic and antidepressant efficacy without significant effects on locomotor activity. Moreover, EMDP at behaviorally active doses, unlike mecamylamine, did not produce eyelid ptosis, suggesting it may produce fewer autonomic side effects than mecamylamine. Thus, the methadone metabolite EMDP may represent a novel therapeutic avenue for the treatment of some affective disorders.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: March 22, 2022
    Assignee: Georgetown University
    Inventors: Kenneth J. Kellar, Yingxian Xiao, Patrick A. Forcelli
  • Publication number: 20220065863
    Abstract: Methods of treating with radiation therapy a subject having cancer, in which the method comprises administering radiation therapy to the subject. The subject does not have an increased risk of having an adverse reaction to radiation therapy. The subject has an increased risk of an adverse reaction to radiation therapy when the subject's level of each component in a component profile from a sample of the subject is altered as compared to the normal level of each component. The component profile may comprise a metabolite panel of geranyl pyrophosphate, glucose-1-phosphate, and 3-hydroxy-3-methylglutaryl-CoA; a lipid panel of LPA 18:0, LPA 16:0, LPC 20:2, CER 24:0, and LPI 16:1; or a combination of these panels. The component profile may also comprise a metabolite panel of metanephrine, tryptophan, xanthurenic acid, and pantothenate; a lipid panel of LPA 18:0, DAG 16:0/18:0, LPA 16:0, and DAG 18:1/18:1; or a combination of these panels.
    Type: Application
    Filed: September 15, 2021
    Publication date: March 3, 2022
    Applicant: Georgetown University
    Inventors: Anatoly Dritschilo, Amrita K. Cheema, Scott Grindrod, Xiaogang Zhong
  • Patent number: 11246881
    Abstract: A construct, or a pharmaceutically acceptable salt thereof, comprising: (a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized; (b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and (c) a siRNA complexed with the poly(L-lysine) of the polymer moiety, wherein the construct is neutralized.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: February 15, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Georgetown University
    Inventors: Jill P. Smith, Stephan Stern, Abdullah Mahmud
  • Patent number: 11247206
    Abstract: A system for determining the presence of cell-free non-coding RNA (cfNCR) biomarkers in interstitial fluid includes a microfluidic device for non-invasively and passively accessing interstitial fluid from a patient. The microfluidic device is formed of a substrate containing multiple vertical micro channels therethrough, wherein at a first end of each of the multiple vertical micro channels a microheater is formed for controllably ablating a portion of dry dead skin cells to access the interstitial fluid; and wherein at a second end of each of the multiple vertical micro channels is a horizontal micro channel for receiving accessed interstitial fluid from a vertical micro channel and guiding the accessed interstitial fluid to a common collection port.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 15, 2022
    Assignee: Georgetown University
    Inventor: Makarand Paranjape
  • Patent number: 11238966
    Abstract: Embodiments of the present systems and methods may provide techniques to predict the success or failure of a drug used for disease treatment. For example, a method of determining drug efficacy may include, for a plurality of patients, generating a directed acyclic graph from health related information of each patient comprising nodes representing a medical event of the patient, at least one first edge connecting the first node to an additional node, each additional edge connecting nodes representing two consecutive medical events, the edge having a weight based on a time difference between the two consecutive medical events, capturing a plurality of features from each directed acyclic graph, generating a binary graph classification model on captured features of each directed acyclic graph, determining a probability that a drug or treatment will be effective using the binary graph classification model, and determining a drug to be prescribed to a patient based on the determined probability.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: February 1, 2022
    Assignee: Georgetown University
    Inventors: Ophir Frieder, Hao-Ren Yao, Der-Chen Chang
  • Patent number: 11232869
    Abstract: A triage system that determines whether a user is likely to have contracted a disease based on sensor data received from a user device (e.g., a smartphone or activity tracker). Some symptoms are identified by comparing sensor data to a predetermined baseline and comparing the difference to a predetermined symptom threshold. Those comparisons are weighted to form a composite metric, which is compared to a composite threshold to determine if the user is likely to have contracted the disease. Because different individuals are at higher risk of contracting certain diseases, the determined based on specific characteristics of the user (e.g., potential comorbidities, age, gender, ethnic, racial, cultural, or economic status, geographic location, level of interaction with other individuals, etc.) that that have been identified in medical literature as increasing the individual's risk.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: January 25, 2022
    Assignee: Georgetown University
    Inventors: Howard Federoff, Ophir Frieder
  • Patent number: 11226945
    Abstract: A knowledge model “overlay” for organizing and analyzing large, dynamic data volumes is implemented as a hypergraph that manifests as a result of a distributed theory-driven data source transformation process. This process maps exponentially growing data into an asymptotically limited information space. Within this space, real-world entities (e.g. people, computers, cities, Earth) and their complex interdependencies (e.g. social networks, connectivity, causal relationships) are represented as attributed hypergraph elements (i.e. both hypervertices and hyperedges). Attributes are represented as state vectors affixed to any hypergraph element. Transformation of source system data into this overlay structure is accomplished with minimal data movement and replication using a universal “pointer” like mechanism that is managed in a decentralized fashion by the respective transformation components.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: January 18, 2022
    Assignee: Georgetown University
    Inventor: J. Cory Smart
  • Patent number: 11219390
    Abstract: A device for introducing at least one antimicrobial in an exposed region of a user's skin caused while accessing interstitial fluid includes a substrate having thereon at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion for forming a micropore in the user's skin. A nanofiber mat loaded with at least one antimicrobial material is arranged on the substrate such that it contacts the user's skin and encircles an opening of the micropore formed by the microheating element. In a preferred embodiment, the at least one antimicrobial material is LL-37.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: January 11, 2022
    Assignee: Georgetown University
    Inventors: Makarand Paranjape, Shruti M. Paranjape
  • Publication number: 20220000819
    Abstract: Provided herein are methods for treating nonalcoholic steatohepatitis (NASH) in a subject, comprising administering to a subject having NASH an effective amount of a CCK receptor inhibitor.
    Type: Application
    Filed: November 5, 2019
    Publication date: January 6, 2022
    Applicant: GEORGETOWN UNIVERSITY
    Inventor: Jill P. SMITH
  • Publication number: 20220000842
    Abstract: The present application is directed to methods and compositions for treating a condition marked by enhanced inflammation in the central nervous system (CNS). The methods comprise administering to a subject in need of treatment of enhanced inflammation in the CNS an inhibitor of an amino acid transporter in inflammatory cells present in the CNS. The compositions of the present invention relate to compositions comprising an inhibitor of an amino acid transporter in inflammatory cells, or a pharmaceutically acceptable salt thereof, wherein the composition is formulated for direct administration into the CNS of a mammal.
    Type: Application
    Filed: October 2, 2019
    Publication date: January 6, 2022
    Applicant: Georgetown University
    Inventors: Jeffrey Huang, Maryna Baydyuk
  • Patent number: 11202792
    Abstract: Provided herein are methods of treating a bone or connective tissue cancer in a subject. The methods comprise administering to the subject an effective amount of a CD99 inhibitor, wherein the CD99 inhibitor is a compound having the formula wherein R, each of which may be the same or different, is hydrogen, or a protecting group; wherein Z is selected from the group consisting of F, Cl and Br; wherein X is H or F; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: December 21, 2021
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Aykut Üren, Haydar Celik, Jeffrey A. Toretsky